Remove 2024 Remove DEA Remove Policy Remove Programs
article thumbnail

U.S. Cannabis Legalization Update: Who’s Still Waiting and Who May Legalize

Veriheal

Despite this massive shift in cannabis policy, however, a few states are still dragging their feet on cannabis legalization. Further, after several failed attempts to legalize medical cannabis, there’s is finally enough steam to put an initiative on the state’s 2024 ballot. Possession of up to 1.5 year prison sentence.

article thumbnail

Publicly Traded Cannabis Company Plans $500M (!) EB-5 Raise (!!)

Canna Law Blog

EB-5 program. The INA contains an immigrant investor program at 8 USC § 1153(b)(5) that allows foreign nationals to apply for permanent residence by making a minimum investment in a new commercial enterprise in the U.S. The program, known as “EB-5”, is much more complex but for or purposes here that will do. Bright Green Corp.,

DEA 70
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How to access and assess ketamine therapy options

The Cannigma

Schedule III substances are subject to certain controls not applicable to all other prescription drugs, including the requirement that a medical professional with a specific license issued by the Drug Enforcement Agency (DEA) must conduct an in-person examination before prescribing it. At-home ketamine treatment programs vary.

Therapy 78
article thumbnail

These 4 Newly Legal States Are Projected Earn an Annual $5 Billion

Veriheal

” This fee — which is designed to support social equity programs — is required to convert up to three medical cannabis dispensaries into dual medical-recreational facilities. However, it’s important to note that — according to the Marijuana Policy Project — each applicant would be required to pay a fee of $3 million.

article thumbnail

Cannabis Trends of 2022

Kind Meds (Cannabis Education Blog)

As policies become more data-driven and progressive, cultivation and production technologies have continued to improve drastically over the past several years. The DEA still classifies cannabis as a Schedule I controlled substance, a designation reserved for drugs with no medical value and a high potential for abuse.